Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL001 phase 3 trial in progranulin mutation-associated frontotemporal dementia
NL-OMON52667Phase 3Recruiting
- Sponsor
- Alector
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of AL001 in frontotemporal dementia (FTD) (3 arms), sponsored by Alector. Primary endpoints: CDR plus NACC FTLD-SB and Long-term safety and tolerability. Started Nov 2021; status: recruiting.
02
Drugs
AL001
03
Conditions
frontotemporal dementia (FTD)
Beyond the preview
Go deeper on NL-OMON52667.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52667.